Back to Gene
CLN6 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CLN6 gene

The CLN6 gene provides instructions for a protein involved in cellular transport, with mutations linked to CLN6 disease, a condition characterized by progressive motor and intellectual decline.

Normal Function

The CLN6 gene provides instructions for a protein whose function is not well understood. The CLN6 protein is found in the endoplasmic reticulum, a structure involved in protein processing and transport. Research suggests that the CLN6 protein regulates the transportation of certain proteins and fats from the endoplasmic reticulum to lysosomes, helping cells dispose of materials they no longer need.

Health Conditions Related to Genetic Changes

CLN6 disease

More than 70 mutations in the CLN6 gene have been found to cause CLN6 disease. This condition impairs motor and mental development, typically starting in early to late childhood, though some cases do not appear until adulthood.

Most CLN6 gene mutations result in the production of an abnormal protein that is quickly degraded, leading to a severe reduction in functional protein. In adult-onset cases, mutations often change single amino acids, resulting in a protein with reduced function that allows enough activity to delay the onset of symptoms.

CLN6 disease is characterized by the accumulation of proteins, peptides, and other substances in lysosomes. These accumulations occur throughout the body, but nerve cells are particularly vulnerable. The progressive death of these nerve cells leads to the movement and intellectual problems associated with the disorder.

Frequently Asked Questions

Consistent seizure control, regular physiotherapy to preserve strength and flexibility, occupational therapy for adaptive equipment, and low‑vision services are essential. Nutritional support and monitoring for swallowing difficulties also reduce complications that can accelerate decline.
Clinicians should be alert when a child between 2 and 10 years old shows a combination of declining motor milestones (e.g., loss of balance or gait), emerging seizures, and early visual problems, especially if MRI reveals cerebral or cerebellar atrophy without another clear cause.
Confirmation requires molecular genetic testing—usually a targeted CLN6 gene panel or whole‑exome sequencing—to detect pathogenic variants; some labs also perform skin‑biopsy fibroblast studies that show the typical lysosomal storage pattern.
Research is focused on adeno‑associated virus (AAV) gene‑therapy delivered to the central nervous system and on small‑molecule drugs that stabilize the mutant CLN6 protein. Families can inquire about ongoing trials through clinicaltrials.gov or by contacting national lysosomal disease networks, which can help with eligibility screening and travel logistics.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab